A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

This Phase I interventional trial (n=16) will evaluate the safety, tolerability, and efficacy of a second psilocybin-assisted group therapy session in treating anxiety and distress in patients with metastatic cancer who had a partial response to their first retreat.

Conducted by the University of Washington, the study aims to assess whether a second psilocybin session can further alleviate anxiety in this patient population.

Participants will receive psilocybin orally on day 0, with an optional booster dose. They will attend individual and group preparation sessions before dosing and integration visits afterward. The primary outcome will measure the incidence of adverse events, while secondary outcomes will track changes in anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). Follow-up assessments will occur at 2, 3, and 6 months post-treatment.

Topic Palliative Care Anxiety Safety Depression
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Washington in Seattle
Research into the therapeutic potential of psychedelics is underway at Washington State University.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.